Table 1 Baseline histological features and changes after 6 months of treatment with orlistat.

Patient	Fat extension before treatment	Fat extension after treatment	Inflammation before treatment	Inflammation after treatment	Fibrosis before treatment	Fibrosis after treatment	Weight change (%)
1	Severe	Severe	A2	A0	F2	F0	−2.9
2	Severe	Mild	A2	A1	F2	F1	−4.5
3	Mild	Normal	A4	A2	F2	F3	−8.4
4	Mild	Normal	A2	A2	F1	F1	−2.4
5	Severe	Mild	A2	A0	F2	F0	−8.2
6	Severe	Severe	A2	A1	F2	F1	−2.3
7	Moderate	ild	A1	A1	F1	F0	−5.5
8	Severe	Severe	A2	A1	F2	F1	+3
9	Severe	Mild	A2	A1	F1	F0	−16.3
10	Severe	Moderate	A2	A2	F2	F1	−3.3
11	Severe	Severe	A3	A2	F3	F1	−7.3
12	Mild	Normal	A1	A0	F1	F1	−6.3
13	Moderate	Mild	A1	A0	F1	F0	−4.1
14	Severe	Mild	A2	A0	F2	F2	−6.9

Fat extension: normal  =  <10%, mild  =  <30%, moderate  =  30–60%, severe  =  >60%. Fibrosis scale: 0  =  none, F1 =  portal, F2  =  portal +septa, F3  =  bridging, F4  =  cirrhosis. Portal & periportal inflammatory activity (A): 0 = normal, 1 = mild, 2 = moderate, 3 = severe.